Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges.

导出 LinkOut

翻译打印收藏纠错

第一作者： De-Hua,Yu

第一单位： College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.

作者： De-Hua,Yu ^[1] ; Zhi-Yuan,Xu ^[2] ; Shaowei,Mo ^[3] ; Li,Yuan ^[3] ; Xiang-Dong,Cheng ^[2] ; Jiang-Jiang,Qin ^[4]

作者单位： College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China. ^[1] Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China. ^[2] First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China. ^[3] College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.;Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China. ^[4]

关键词 MDM2 MDMX inhibitors oncogene p53 tumor suppressor

DOI 10.3389/fonc.2020.01389

PMID 32850448

发布时间 2020-09-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2020年10卷

1389页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除